CD274 and neoplasm: The NExT platform showed the enhanced interaction with tumor cells through corresponding ligands including PD-L1, Gelectin-3, protein fibrinogen-like protein 1, Gelectin-9, and Ceacam-1, thereby improving active targeting and delivery.121